Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Spotlight on Clinical Response

Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine

James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer and Georgina V. Long
James S. Wilmott
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Varsha Tembe
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie R. Howle
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raghwa Sharma
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John F. Thompson
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Rizos
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger S. Lo
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard F. Kefford
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard A. Scolyer
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgina V. Long
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-12-0530 Published December 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: September 2012 to February 2021

AbstractFull-text HTMLPDF
Total527819482396

Cited By

Article Information

Volume 11, Issue 12, pp. 2704-2708

DOI 
https://doi.org/10.1158/1535-7163.MCT-12-0530
PubMed 
22962325

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received May 28, 2012
  • Revision received August 26, 2012
  • Accepted August 31, 2012
  • Published first September 7, 2012.

Article Versions

  • Previous version (September 7, 2012 - 12:57).
  • Previous version (November 30, 2012 - 12:43).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2012 American Association for Cancer Research.

Author Information

  1. James S. Wilmott1,2,
  2. Varsha Tembe1,2,3,4,
  3. Julie R. Howle1,2,5,
  4. Raghwa Sharma5,
  5. John F. Thompson1,2,6,
  6. Helen Rizos1,2,3,4,
  7. Roger S. Lo7,8,9,
  8. Richard F. Kefford1,2,3,4,5,
  9. Richard A. Scolyer1,2,6, and
  10. Georgina V. Long1,2,3,4,5
  1. Authors' Affiliations: 1Melanoma Institute Australia; 2The University of Sydney; 3Westmead Institute for Cancer Research; 4Westmead Millennium Institute; 5Westmead Hospital; 6Royal Prince Alfred Hospital; Sydney, New South Wales, Australia; 7Divisions of Dermatology/Department of Medicine; 8Jonsson Comprehensive Cancer Center; and 9Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California
  1. Corresponding Author:
    Georgina V. Long, Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Road, North Sydney 2060, New South Wales, Australia. Phone: 61-2-9911-7200; Fax: 61-2-9954-9435; E-mail: georgina.long{at}sydney.edu.au
  1. J. S. Wilmott and V. Tembe contributed equally to this work.

View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 11 (12)
December 2012
Volume 11, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer and Georgina V. Long
Mol Cancer Ther December 1 2012 (11) (12) 2704-2708; DOI: 10.1158/1535-7163.MCT-12-0530

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer and Georgina V. Long
Mol Cancer Ther December 1 2012 (11) (12) 2704-2708; DOI: 10.1158/1535-7163.MCT-12-0530
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results and Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Erlotinib Response EGFR+ NSCLC with Squamous Element
  • Chondrosarcoma and TRAIL Targeted Therapy
Show more Spotlight on Clinical Response
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement